Stryker (NYSE:SYK) Stock Price Target Lowered at Citigroup

Stryker (NYSE:SYK) had its price objective reduced by Citigroup from $360.00 to $315.00 in a report published on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the medical technology company’s stock.

SYK has been the subject of a number of other research reports. Piper Sandler reduced their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. UBS Group assumed coverage on Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. Johnson Rice downgraded Stryker to a “hold” rating in a research note on Friday. Stifel Nicolaus cut their price objective on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Thursday. Sixteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $355.84.

Stryker Trading Down 6.5%

Shares of SYK stock opened at $291.56 on Friday. Stryker has a 1 year low of $267.00 and a 1 year high of $389.33. The firm has a fifty day moving average price of $292.83 and a 200-day moving average price of $324.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 2.01 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.83% and a net margin of 13.78%. The company had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same period in the prior year, the business posted $3.19 earnings per share. Stryker’s revenue for the quarter was up 7.6% compared to the same quarter last year. As a group, equities analysts predict that Stryker will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a $0.88 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Amundi increased its position in shares of Stryker by 18.3% during the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after purchasing an additional 192,447 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after buying an additional 65,333 shares during the period. Veritas Asset Management LLP bought a new stake in Stryker in the second quarter worth $168,057,000. Bank of America Corp DE bought a new stake in Stryker in the second quarter worth $1,404,284,000. Finally, Rakuten Investment Management Inc. purchased a new position in Stryker during the second quarter worth $18,646,000. Institutional investors own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.